{"id":52711,"date":"2023-01-09T19:02:08","date_gmt":"2023-01-09T18:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/"},"modified":"2023-01-09T19:02:08","modified_gmt":"2023-01-09T18:02:08","slug":"corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/","title":{"rendered":"Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective &#8211; The Views of 240 Patient Groups &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5328704\/the-corporate-reputation-of-pharma-in-2021-the?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=pj9x5j&amp;utm_campaign=1804229+-+Corporate+Reputation+of+Pharma+in+United+States%2C+2021-2022%3A+The+Patient+Perspective+-+The+Views+of+240+Patient+Groups&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;The Corporate Reputation of Pharma in 2021 &#8211; The Patient Perspective &#8211; USA Edition &#8211; The Views of 240 USA Patient Groups&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230109005758\/en\/1680748\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230109005758\/en\/1680748\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe &#8216;Corporate Reputation of Pharma&#8217; Survey &#8211; US Edition, is now in its 9th year, and two years into the Covid-19 pandemic. Between November 2021-February 2022, the survey collected the opinions of 240 US-based patient groups on the performance of the pharmaceutical industry during 2021.\n<\/p>\n<p>\nPatient groups responding to the &#8216;Corporate Reputation of Pharma&#8217; survey are uniquely positioned to comment on the pharma industry&#8217;s performance during the pandemic. Patient groups not only understand the perceptions of patients but are also the only healthcare stakeholder to network with all other stakeholders in the healthcare system.\n<\/p>\n<p>\n<strong>The report provides highlights on:<\/strong>\n<\/p>\n<ul>\n<li>\nHow the analyst measures pharma&#8217;s corporate reputation from a patient perspective\n<\/li>\n<li>\nThe headline results of the 2021 USA survey\n<\/li>\n<li>\nThe companies included in the 2021 US analysis\n<\/li>\n<li>\nThe profiles of 2021&#8217;s respondent US patient groups\n<\/li>\n<\/ul>\n<p>\n<strong>SUMMARY OF RESULTS<\/strong>\n<\/p>\n<p>\n<strong>FINDINGS AT INDUSTRY LEVEL<\/strong>\n<\/p>\n<p>\nThe 240 US patient groups responding to the 2021 survey rated the pharma industry more favourably for corporate reputation than their predecessors in previous years. 67% of 2021&#8217;s respondent patient groups stated that the industry had an &#8220;Excellent&#8221; or &#8220;Good&#8221; corporate reputation, against 57% saying the same in 2020.\n<\/p>\n<p>\nThe positivity of 2021&#8217;s respondent patient groups appears to be largely driven by the pharma industry&#8217;s response to the Covid-19 pandemic &#8211; specifically, the success some US companies have had at developing vaccines and treatments. In total 81% of 2021&#8217;s respondent patient groups stated that pharma was &#8220;Very effective&#8221; or &#8220;Effective&#8221; at providing support to patients during the pandemic, the same percentage as in 2020.\n<\/p>\n<p>\nDuring 2021, the Covid-19 pandemic continued to monopolise public life in the USA. Prior to the pandemic, other, longer-term problems &#8211; particularly health inequities, rising drug pricing and pharma&#8217;s perceived lack of transparency &#8211; dominated political debate in the field of healthcare. For patients with chronic diseases, these issues have not gone away.\n<\/p>\n<p>\nAlready, the analyst&#8217;s 2021 figures indicate a growing impatience with pharma among US patient groups. 2021&#8217;s 240 respondent US patient groups registered significant drops in their approval ratings when asked in the &#8216;Corporate Reputation&#8217; survey about specific pharma activities of importance to patients and patient groups &#8211; especially patient safety, patient centricity, patient information, and integrity.\n<\/p>\n<p>\n<strong>COMPANY RANKINGS<\/strong>\n<\/p>\n<p>\nThe top-three pharma companies out of 41 companies, ranked for their overall corporate reputation in 2021 (assessed by respondent patient groups familiar with the company): ViiV Healthcare, 1st &#8211; Horizon Therapeutics, 2nd &#8211; Pfizer, 3rd.\n<\/p>\n<p>\nThe top-three &#8216;big-pharma&#8217; companies out of 13 companies, ranked for overall corporate reputation in 2021 (assessed by respondent patient groups familiar with the company): Pfizer, 1st &#8211; Genentech (Roche), 2nd &#8211; and Janssen, 3rd.\n<\/p>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<ul>\n<li>\nExecutive summary\n<\/li>\n<li>\nUS patient-group relationships with pharma, 2021\n<\/li>\n<li>\nIndustry-wide findings in the USA, 2021\n<\/li>\n<li>\nRankings of 41 pharma companies in the USA, 2021 v. 2020, as assessed by respondent US patient groups familiar with the companies\n<\/li>\n<li>\nRankings of 34 pharma companies in the USA, 2021 v. 2020, as assessed by respondent US patient groups working with the companies\n<\/li>\n<li>\nRankings of 13 &#8216;big-pharma&#8217; companies in the USA, 2021 v. 2020, as assessed by respondent US patient groups familiar with the companies\n<\/li>\n<li>\nRankings of 13 &#8216;big-pharma&#8217; companies in the USA, 2021 v. 2020, as assessed by respondent US patient groups working with the companies\n<\/li>\n<li>\nRankings of generic pharma companies in the USA, 2021 v. 2020, as assessed by respondent US patient groups familiar with the companies\n<\/li>\n<li>\nProfiles of the 41 companies, 2021 (v. 2020)\n<\/li>\n<\/ul>\n<p>\n<strong>Each company is profiled by the following measures:<\/strong>\n<\/p>\n<ul>\n<li>\nThe number of respondent US patient groups familiar, and working, with the company, 2021.\n<\/li>\n<li>\nThe profile of the respondent US patient groups familiar with the company (the number of patients reached; specialties; and geographic remit), 2021.\n<\/li>\n<li>\nThe types of relationships that the company had with its respondent US patient-group partners, 2021.\n<\/li>\n<li>\nCompany performance in the USA at the individual indicators of corporate reputation in 2021-as assessed by respondent US patient groups familiar, and working, with the company.\n<\/li>\n<li>\nCompetitors&#8217; relationships in 2021 with the company&#8217;s respondent US patient-group partners.\n<\/li>\n<li>\nOverall rankings in the USA for the company-as assessed by respondent US patient groups familiar, and working, with the company, 2021 v. 2020.\n<\/li>\n<li>\nCompany rankings in the USA for each of the indicators-as assessed by respondent US patient groups familiar, and working, with the company, 2021 v. 2020.\n<\/li>\n<li>\nSnapshot view: where the company sits in the US corporate tiers for each of the indicators (in the higher, the middle, or the lower tier)-as assessed by respondent US patient groups familiar, and working, with the company, 2021.\n<\/li>\n<li>\nOverall rankings of the company in the USA, 2016-2021-expressed on the Patient Corporate Reputation Index (PCRI), a measure designed to standardise the analyst&#8217;s ranking data (preventing results being skewed by the differing numbers of companies included in the US historic analyses over the various years). PCRI ranking is from 0 to 1, with 1 being the best (the highest rank)-as assessed by respondent US patient groups familiar with the company.\n<\/li>\n<\/ul>\n<p>\n<strong>Profiles of the 41 companies, 2021<\/strong>\n<\/p>\n<ul>\n<li>\nAbbVie\n<\/li>\n<li>\nAcorda Therapeutics\n<\/li>\n<li>\nAmgen\n<\/li>\n<li>\nAstellas\n<\/li>\n<li>\nAstraZeneca\n<\/li>\n<li>\nBayer\n<\/li>\n<li>\nBiogen\n<\/li>\n<li>\nBoehringer\n<\/li>\n<li>\nBristol Myers Squibb\n<\/li>\n<li>\nChiesi Farmaceutici\n<\/li>\n<li>\nCSL Behring\n<\/li>\n<li>\nDaiichi Sankyo\n<\/li>\n<li>\nDr Reddy&#8217;s\n<\/li>\n<li>\nEisai\n<\/li>\n<li>\nEli Lilly\n<\/li>\n<li>\nEMD Serono (Merck KGaA)\n<\/li>\n<li>\nFerring\n<\/li>\n<li>\nGenentech (Roche)\n<\/li>\n<li>\nGilead Sciences\n<\/li>\n<li>\nGrifols\n<\/li>\n<li>\nGSK\n<\/li>\n<li>\nHorizon Therapeutics\n<\/li>\n<li>\nIpsen\n<\/li>\n<li>\nJanssen\n<\/li>\n<li>\nLundbeck\n<\/li>\n<li>\nMerck &amp; Co (MSD)\n<\/li>\n<li>\nMylan\n<\/li>\n<li>\nNovartis\n<\/li>\n<li>\nNovo Nordisk\n<\/li>\n<li>\nOctapharma\n<\/li>\n<li>\nOtsuka\n<\/li>\n<li>\nPfizer\n<\/li>\n<li>\nSandoz\n<\/li>\n<li>\nSanofi\n<\/li>\n<li>\nServier\n<\/li>\n<li>\nSun Pharma\n<\/li>\n<li>\nTakeda\n<\/li>\n<li>\nTeva\n<\/li>\n<li>\nUCB\n<\/li>\n<li>\nVertex\n<\/li>\n<li>\nViiV Healthcare\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5328704\/the-corporate-reputation-of-pharma-in-2021-the?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=pj9x5j&amp;utm_campaign=1804229+-+Corporate+Reputation+of+Pharma+in+United+States%2C+2021-2022%3A+The+Patient+Perspective+-+The+Views+of+240+Patient+Groups&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/7jcyom<\/a>\n<\/p>\n<p>\n<strong>About ResearchAndMarkets.com<\/strong>\n<\/p>\n<p>\nResearchAndMarkets.com is the world&#8217;s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;t&#x6f;&#x3a;&#x70;&#114;es&#x73;&#x40;&#114;&#101;s&#x65;&#x61;&#x72;&#99;ha&#x6e;&#x64;&#109;&#97;r&#x6b;&#x65;&#x74;&#115;&#46;c&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x72;&#101;&#x73;s&#x40;r&#101;&#x73;&#101;&#x61;&#114;&#x63;h&#x61;n&#100;&#x6d;&#97;&#x72;k&#x65;t&#x73;&#x2e;&#99;&#x6f;&#109;<\/a><\/p>\n<p>For E.S.T. Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;The Corporate Reputation of Pharma in 2021 &#8211; The Patient Perspective &#8211; USA Edition &#8211; The Views of 240 USA Patient Groups&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The &#8216;Corporate Reputation of Pharma&#8217; Survey &#8211; US Edition, is now in its 9th year, and two years into the Covid-19 pandemic. Between November &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52711","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective - The Views of 240 Patient Groups - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective - The Views of 240 Patient Groups - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;The Corporate Reputation of Pharma in 2021 &#8211; The Patient Perspective &#8211; USA Edition &#8211; The Views of 240 USA Patient Groups&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The &#8216;Corporate Reputation of Pharma&#8217; Survey &#8211; US Edition, is now in its 9th year, and two years into the Covid-19 pandemic. Between November ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-09T18:02:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230109005758\/en\/1680748\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective &#8211; The Views of 240 Patient Groups &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2023-01-09T18:02:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\\\/\"},\"wordCount\":995,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005758\\\/en\\\/1680748\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\\\/\",\"name\":\"Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective - The Views of 240 Patient Groups - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005758\\\/en\\\/1680748\\\/21\\\/logo.jpg\",\"datePublished\":\"2023-01-09T18:02:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005758\\\/en\\\/1680748\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005758\\\/en\\\/1680748\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective &#8211; The Views of 240 Patient Groups &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective - The Views of 240 Patient Groups - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective - The Views of 240 Patient Groups - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;The Corporate Reputation of Pharma in 2021 &#8211; The Patient Perspective &#8211; USA Edition &#8211; The Views of 240 USA Patient Groups&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The &#8216;Corporate Reputation of Pharma&#8217; Survey &#8211; US Edition, is now in its 9th year, and two years into the Covid-19 pandemic. Between November ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-09T18:02:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230109005758\/en\/1680748\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective &#8211; The Views of 240 Patient Groups &#8211; ResearchAndMarkets.com","datePublished":"2023-01-09T18:02:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/"},"wordCount":995,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230109005758\/en\/1680748\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/","name":"Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective - The Views of 240 Patient Groups - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230109005758\/en\/1680748\/21\/logo.jpg","datePublished":"2023-01-09T18:02:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230109005758\/en\/1680748\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230109005758\/en\/1680748\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/corporate-reputation-of-pharma-in-united-states-2021-2022-the-patient-perspective-the-views-of-240-patient-groups-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective &#8211; The Views of 240 Patient Groups &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52711"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52711\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}